Axonics Modulation Technologies (AXNX) came out with quarterly earnings of $0.16 per share, beating the Zacks Consensus Estimate of $0.13 per share. This compares to earnings of $0.08 per share a year ...

In a report released yesterday, Shagun Singh Chadha from RBC Capital maintained a Hold rating on Axonics Modulation Technologies (AXNX – Research Report), with a price target of $71.00. The company’s ...

Axonics Modulation Technologies (AXNX – Research Report) received a Hold rating and price target from Wolfe Research analyst Michael Polark yesterday. The company’s shares closed yesterday at $69.36.

IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc., developer of the first rechargeable Sacral Neuromodulation (r-SNM™) system for the treatment of urinary and fecal dysfunction, ...

Axonics Modulation Technologies (AXNX) came out with quarterly earnings of $0.13 per share, beating the Zacks Consensus Estimate of $0.06 per share. This compares to earnings of $0.01 per share a year ...

Axonics Modulation Technologies (AXNX) came out with a quarterly loss of $0.89 per share versus the Zacks Consensus Estimate of a loss of $0.73. This compares to loss of $2.67 per share a year ago.

IRVINE, Calif. (AP) — IRVINE, Calif. (AP) — Axonics Modulation Technologies Inc. (AXNX) on Thursday reported second-quarter net income of $6.9 million, after reporting a loss in the same period a year ...

Weighted-average shares used to compute basic and diluted net loss per share ...

IRVINE, Calif. (AP) — IRVINE, Calif. (AP) — Axonics Modulation Technologies Inc. (AXNX) on Tuesday reported a loss of $19.1 million in its first quarter. On a per-share basis, the Irvine, ...

Medical device giant Boston Scientific announced a $3.7 billion deal on Monday to augment its urology portfolio. The company is acquiring Axonics, a maker of neurostimulation devices that treat ...